MétaCan
Menu
Back to cohort
Record W4404883387 · doi:10.1002/alz.14264

ADNI Biomarker Core: A review of progress since 2004 and future challenges

2024· review· en· W4404883387 on OpenAlexafffund
Leslie M. Shaw, Magdalena Korecka, Edward B. Lee, Katheryn A Q Cousins, Hugo Vanderstichele, Suzanne E. Schindler, Duygu Tosun, Mari L. DeMarco, Magdalena Brylska, Yang Wan, Samantha C. Burnham, Alexandria Sciulli, Amberley Vulaj, Thomas F. Tropea, Alice Chen‐Plotkin, David A. Wolk

Bibliographic record

VenueAlzheimer s & Dementia · 2024
Typereview
Languageen
FieldMedicine
TopicDementia and Cognitive Impairment Research
Canadian institutionsUniversity of British Columbia
FundersNational Institute of Biomedical Imaging and BioengineeringCanadian Institutes of Health ResearchNational Institutes of HealthGenentechIXICOH. Lundbeck A/SServierEisaiNorthern California Institute for Research and EducationPfizerNovartis Pharmaceuticals CorporationUniversity of Southern CaliforniaBiogenEli Lilly and CompanyBristol-Myers SquibbBioClinicaU.S. Department of DefenseAlzheimer's Disease Neuroimaging InitiativeMeso Scale DiagnosticsNational Institute on AgingAlzheimer's Association
KeywordsBiobankBiomarkerBiomarker discoveryAlzheimer's Disease Neuroimaging InitiativeMedicineDiseaseBioinformaticsInternal medicineAlzheimer's diseaseProteomicsChemistryBiology

Abstract

fetched live from OpenAlex

BACKGROUND: We describe the Alzheimer's Disease Neuroimaging Initiative (ADNI) Biomarker Core major activities from October 2004 to March 2024, including biobanking ADNI cerebrospinal fluid (CSF), plasma, and serum biofluid samples, biofluid analyses for Alzheimer's disease (AD) biomarkers in the Biomarker Core and various non-ADNI laboratories, and continuous assessments of pre-analytics. RESULTS: Validated immunoassay and mass spectrometry-based assays were performed in CSF with a shift to plasma, a more accessible biofluid, as qualified assays became available. Performance comparisons across different CSF and plasma AD biomarker measurement platforms have enriched substantially the ADNI participant database enabling method performance determinations for AD pathology detection and longitudinal assessments of disease progression. DISCUSSION: Close collaboration with academic and industrial partners in the validation and implementation of AD biomarkers for early detection of disease pathology in treatment trials and ultimately in clinical practice is a key factor for the success of the work done in the Biomarker Core. HIGHLIGHTS: Describe ADNI Biomarker Core biobanking and sample distribution from 2007 to 2024. Discuss validated mass spectrometry and immunoassay methods for ADNI biofluid analyses. Review collaborations with academic and industrial partners to detect AD and progression. Discuss major challenges, and progress to date, for co-pathology detection. Implementation in the ATN scheme: co-pathology and modeling disease progression.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.005
metaresearch head score (Gemma)0.006
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.006
Threshold uncertainty score0.024

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0050.006
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0020.001
Bibliometrics0.0060.006
Science and technology studies0.0000.001
Scholarly communication0.0020.003
Open science0.0020.001
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0030.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.099
GPT teacher head0.406
Teacher spread0.307 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations24
Published2024
Admission routes2
Has abstractyes

Explore more

Same venueAlzheimer s & DementiaSame topicDementia and Cognitive Impairment ResearchFrench-language works237,207